The systematic review by Wanigasinghe et al. demonstrated that although both treatments show similar efficacy in the management of infantile spasms, ACTH was associated with a higher incidence of these adverse effects.1This difference in safety profiles should be considered when choosing a therapeutic strategy and further investigated in future randomized clinical trials. This evidence concerns the gene POMC and infantile spasms.